We are driven by the desire to save children’s lives, develop the first treatment for MVID, and to give patients the chance to live a healthy life.
At the Yale School of Medicine, Dr. Dmitry Kravtsov identified how the immaturity of intestinal cells leads to the severity of diarrhea in MVID patients. He had to choose between two opportunities: to continue in-depth research or to translate available data into the first treatment for MVID. Dmitry chose the latter and worked with a team of researchers and entrepreneurs, forming what is now Vanessa Biotech.
Our diverse team consists of members who specialize in medicine, biomedical research, physics, chemistry, engineering, biomedical device development, marketing, law and regulatory affairs.